Adult T-cell leukemia/lymphoma and HTLV-1

被引：34

作者：

Mahieux R. ^{[1
]}

Gessain A. ^{[1
]}

机构：

[1] CNRS URA 3015, Department of Virology, Institut Pasteur, 75724 Paris Cedex 15

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 4期

关键词：

Alemtuzumab; Arsenic Trioxide; Proviral Load; ATLL Cell; ATLL Patient;

D O I：

10.1007/s11899-007-0035-x

中图分类号：

学科分类号：

摘要：

Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million individuals worldwide. This oncoretrovirus can be transmitted in three ways: horizontally (sexually), vertically (mother to child), and via blood transfusion. HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1- associated myelopathy (TSP/HAM). ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type. Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations. This article discusses a number of recent treatments including antiretroviral therapy, aggressive chemotherapy, and allogeneic bone-marrow transplantation, as well as new drugs. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：257 / 264

页数：7

共 55 条

[1]

Poiesz B.J., Ruscetti F.W., Gazdar A.F., Et al., Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma, Proc Natl Acad Sci U S A, 77, pp. 7415-7419, (1980)

[2]

Takatsuki T., Adult T-cell leukemia in Japan, Topics in Hematology, pp. 73-77, (1977)

[3]

Yoshida M., Miyoshi I., Hinuma Y., Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease, Proc Natl Acad Sci U S A, 79, pp. 2031-2035, (1982)

[4]

Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L., Global epidemiology of HTLV-1 infection and associated diseases, Oncogene, 24, pp. 6058-6068, (2005)

[5]

Gessain A., Epidemiology of HTLV-1, Human T-Cell Lymphotropic Virus Type 1, pp. 34-63, (1996)

[6]

Ureta-Vidal A., Angelin-Duclos C., Tortevoye P., Et al., Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: Implication of high antiviral antibody titer and high proviral load in carrier mothers, Int J Cancer, 82, pp. 832-836, (1999)

[7]

Roucoux D.F., Wang B., Smith D., Et al., A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II, J Infect Dis, 191, pp. 1490-1497, (2005)

[8]

Manns A., Murphy E.L., Wilks R., Et al., Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients, Blood, 77, pp. 896-905, (1991)

[9]

Wattel E., Vartanian J.P., Pannetier C., Wain-Hobson S., Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy, J Virol, 69, pp. 2863-2868, (1995)

[10]

Verdonck K., Gonzalez E., Van Dooren S., Et al., Human T-lymphotropic virus 1: Recent knowledge about an ancient infection, Lancet Infect Dis, 7, pp. 266-281, (2007)

← 1 2 3 4 5 6 →